Evidence map›Paper›PMID 29317033›Full record

ArticleSeminars in ultrasound, CT, and MR2018

Emerging Breast Imaging Technologies on the Horizon.

Srinivasan Vedantham, Andrew Karellas

Abstract read
In one paragraph

Article in Seminars in ultrasound, CT, and MR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Srinivasan VedanthamDepartment of Medical Imaging, University of Arizona College of Medicine, Banner University Medical Center, Tucson, AZ. Electronic address: svedantham@radiology.arizona.edu.
Andrew KarellasDepartment of Medical Imaging, University of Arizona College of Medicine, Banner University Medical Center, Tucson, AZ.

Funding

Towards screening with high-resolution, low-dose, dedicated breast CTR01CA199044 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SRINIVASAN VEDANTHAM · 2016 to 2026
$6.1M
Towards in vivo imaging with benchtop x-ray fluorescence computed tomographyR01EB020658 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHO, SANG HYUN · 2016 to 2019
$3.0M
Reducing mastectomy rates in invasive lobular carcinoma by high-resolution 3D breast CTR01CA195512 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI VEDANTHAM, SRINIVASAN · 2015 to 2017
$757k
NCI NIH HHS R01 CA195512NCI NIH HHS R01 CA199044NIBIB NIH HHS R01 EB020658
6 · The paper itself

Abstract

Early detection of breast cancers by mammography in conjunction with adjuvant therapy has contributed to reduction in breast cancer mortality. Mammography remains the "gold-standard" for breast cancer screening but is limited by tissue superposition. Digital breast tomosynthesis and more recently, dedicated breast computed tomography have been developed to alleviate the tissue superposition problem. However, all of these modalities rely upon x-ray attenuation contrast to provide anatomical images, and there are ongoing efforts to develop and clinically translate alternative modalities. These emerging modalities could provide for new contrast mechanisms and may potentially improve lesion detection and diagnosis. In this article, several of these emerging modalities are discussed with a focus on technologies that have advanced to the stage of in vivo clinical evaluation.

Indexed as

BreastBreast NeoplasmsDiagnostic ImagingFemaleHumansMammography

Identifiers

PMID29317033
PMCPMC5773258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.